Bavarian Nordic Announces Initiation Of Safety And Immunogenicity Study Of Ebola Vaccine Regimen In Sierra Leone

Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today the initiation of a new clinical study of the Ebola prime-boost vaccine regimen that combines Bavarian Nordic's MVA-BN® Filo vaccine with the Ad26.ZEBOV vaccine from Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news